This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           October 22, 2014

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store

 

Screening for Lynch syndrome improves health outcomes at an acceptable cost
Oncology Nurse Advisor
Screening families of patients with colorectal cancer for a genetic condition would reduce their risk of developing colorectal, uterine, and ovarian cancers, new research has found. Testing for Lynch syndrome in patients younger than 50 years who have colorectal cancer was found to be cost-effective in this study, published in Health Technology Assessment.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  




SGO NEWS


SGO Practice Survey focus of Annual Meeting Member Forum
The SGO thanks all full and candidate members who filled out the SGO Practice Survey. The response rate exceeded current industry survey trends and a final report will be available prior to the 2015 SGO Annual Meeting in Chicago, March 28-31, 2015. The Annual Meeting’s Member Forum will focus on the results of the survey, which provide in-depth clinical implications for SGO members. Those who completed the survey will receive the 2015 State of the Subspecialty report at no charge.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


OVARIAN CANCER


Diet may influence ovarian cancer survival
Reuters
Women with healthier diets before an ovarian cancer diagnosis are less likely to die in the years following the cancer than women with poorer diets, according to a new study. The exceptions were women with diabetes or a high waist circumference, which is often linked to diabetes. A healthy diet before diagnosis may indicate a stronger immune system and, indirectly, the capacity to respond favorably to cancer therapy, said lead author of the study published in Journal of the National Cancer Institute.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
PRODUCT SHOWCASE
  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.
 


Promising treatments on horizon in ovarian cancer
OncLive
The treatment of women with advanced ovarian cancer is set to undergo a substantial transformation, due to an explosion of clinical trials exploring promising novel treatment options. At this point, there are 4 main groups of therapies under investigation for patients with ovarian cancer: PARP inhibitors, vaccines, anti-PD-1/PD-L1 therapies, and anti-angiogenic therapies. For further perspective on the evolving field, OncLive interviewed Richard T. Penson, MD, Bradley J. Monk, MD, and Krishnansu S. Tewari, MD, on the changing landscape in the treatment of ovarian cancer.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Study identifies a method for optical detection and laser-based photo destruction of ovarian cancer cells
Medical Xpress
Research conducted by Baharak Bahmani, PhD, Yadir Guerrero, BS, Danielle Bacon, Vikas Kundra, MD, PhD, Valentine I. Vullev, PhD, and Bahman Anvari, PhD was selected as Editor's Choice for the September 2014 issue of Lasers in Surgery and Medicine (LSM). The study demonstrates the effectiveness of a nano-structured system for combined near infrared (NIR) fluorescence imaging of human epidermal growth factor receptor-2 (HER2) over-expression, as a biomarker of ovarian cancer cells, and photothermal destruction of these cells in vitro.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




PREVENTION


'What can I do to reduce my risk for cancer?'
Medscape (Free login required)
The new European Code Against Cancer, launched Oct. 14, outlines 12 things that individuals can do to reduce their risk for cancer. Top of the list is not using any form of tobacco, followed by healthy body weight, avoiding too much sun and alcohol, but there are also several new recommendations — about radon, breast-feeding, and hormone replacement therapy (HRT), and also about HPV vaccination and organized cervical cancer screening.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


RESEARCH


Modeling tumor dormancy: What makes a tumor switch from dormant to malignant?
Science Daily
A new computational model may help illuminate the conditions surrounding tumor dormancy and the switch to a malignant state. The so-called cellular automaton model, described in PLOS ONE, simulated various scenarios of tumor growth leading to tumor suppression, dormancy or proliferation.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


BREAST CANCER


Genetic variant protects some Latina women from breast cancer
Science Daily
A genetic variant common in Latina women protects against breast cancer, an international research collaboration, published in Nature, has found. The variant, a difference in just one of the three billion "letters" in the human genome known as a single-nucleotide polymorphism (SNP), originates from indigenous Americans and confers significant protection from breast cancer, particularly the more aggressive estrogen receptor-negative forms of the disease, which generally have a worse prognosis.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Trastuzumab continues to show life for HER2-positive early stage breast cancer
Science Codex
After following breast cancer patients for an average of eight-plus years, researchers say that adding trastuzumab to chemotherapy significantly improved the overall and disease-free survival of women with early stage HER2-positive breast cancer. They found that the use of trastuzumab produced a 37 percent improvement in survival and a 40 percent reduction in risk of cancer occurrence, compared to patients treated with chemotherapy alone. These findings, published in the Journal of Clinical Oncology, demonstrate how important trastuzumab has been to the treatment of this form of breast cancer, says the study's lead author, Edith A. Perez, MD, deputy director at large, Mayo Clinic Cancer Center and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


 



Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news


Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

Oct. 15, 2014
Oct. 8, 2014
Oct. 1, 2014
Sept. 17, 2014






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063